时珍国医国药2026，Vol.37Issue(7)：1240-1245,6.DOI:10.70976/j.1008-0805.SZGYGY-2026-0706
基于动力蛋白调控NLRP3转运探讨生骨再造丸对激素性股骨头坏死的影响
Effect of Shenggu Zaizao Pill(生骨再造丸)on BMSCs pyroptosis by regulating dynein-mediated NLRP3 transport
摘要
Abstract
Objective To explore the key links and mechanisms of Shenggu Zaizao Pill(生骨再造丸,SGZZP)in treating steroid-associated necrosis of the femoral head(SANFH),investigate the relationship between SANFH pathogenesis and dynein-mediated NLRP3 inflammasome regulation,and clarify the therapeutic targets of SGZZP,thereby elucidating its pharmacological mechanism.Methods BMSCs were divided into a control group,a dexamethasone(Dex)+lipopolysaccharide(LPS)model group,a model group treated with the dynein inhibitor Dynarrestin,and a model group treated with SGZZP-containing serum.After respective treatments,cells were collected for analysis.Cell viability was assessed using a CCK-8 assay.The apoptosis rate was measured by flow cytometry(FCM).The protein expression levels of Dynein,NLRP3,Caspase-1,and GSDMD were determined by Western blot(WB).The con-centrations of IL-1β and IL-18 in the cell culture supernatant were measured by ELISA.Results Compared with the control group,the Dex+LPS model group exhibited decreased cell viability and increased apoptosis.The protein expression of Dynein,NLRP3,Caspase-1,and GSDMD was significantly up-regulated(P<0.0001).as well as the concentrations of IL-1β and IL-18,were markedly elevated(P<0.0001).In contrast,both Dynarrestin and SGZZP-containing serum treatment increased cell viability and reduced apoptosis com-pared to the model group.GSDMD and the concentrations of IL-1β and IL-18(P<0.0001).Conclusion SGZZP inhibits Dynein-mediated microtubule-dependent transport of NLRP3,which subsequently suppresses NLRP3 inflammasome assembly and effectively alleviates BMSCs pyroptosis.关键词
生骨再造丸/动力蛋白/NLRP3/焦亡/激素性股骨头坏死Key words
Shenggu Zaizao Pills(生骨再造丸)/Dynein/NLRP3/Pyroptosis/Steroid-associated necrosis of the femoral head分类
医药卫生引用本文复制引用
曹林忠,马小成..基于动力蛋白调控NLRP3转运探讨生骨再造丸对激素性股骨头坏死的影响[J].时珍国医国药,2026,37(7):1240-1245,6.基金项目
国家自然科学基金(82160915 （）
81860859) （）
